CAMP4 Receives EU Approvals to Begin CMP-002 Phase 1/2 Trial

CAMP4 Therapeutics said it received clinical trial application approval from regulatory authorities and ethics committees in multiple EU countries to initiate a global Phase 1/2 trial of CMP-002.